Continued access to avutometinib and defactinib for recurrent low-grade serous ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial provides continued access to the combination of avutometinib and defactinib for people with recurrent low-grade serous ovarian cancer who are already benefiting from this treatment in a previous study. The goal is to allow ongoing treatment while collecting more safety and effectiveness data.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently receiving avutometinib plus defactinib in the RAMP-201 study and have not permanently stopped this treatment.
- Your doctor believes you are still benefiting from the treatment (e.g., your disease has not grown or has shrunk).
- If you are able to become pregnant, you must use highly effective birth control during the study and for 30 days after the last dose, and have a negative pregnancy test before starting.
- You must be willing and able to provide written consent to participate.
- You must not have had your disease get worse or stopped treatment in the RAMP-201 study for any reason.
- You must not have started any other cancer treatment or joined another clinical trial since being in the RAMP-201 study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether regorafenib (a targeted pill) plus fulvestrant (an injection that lowers estrogen signaling) can slow down recurrent low-grade serous ovarian cancer. It may help people whose cancer has returned after prior treatments.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
This trial tests whether a combination of medications (hydroxychloroquine, everolimus, and others) can help keep ovarian cancer from coming back after successful platinum chemotherapy plus Avastin. It is for people whose cancer responded well to their most recent chemo and who can continue Avastin maintenance.
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.